Vanda Pharmaceuticals seeks FDA nod for breakthrough psoriasis drug
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
This launch is part of the company's strategy to expand its nutraceutical portfolio
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Subscribe To Our Newsletter & Stay Updated